Clinical Research

Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert

Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert

A group of medical doctors and nurses attending a professional training session on medical cannabis, representing healthcare professionals gaining CPD accreditation in the UK.

Healthcare professionals attending the Cannabis Health Symposium in London next month will be able to gain Continuing Professional Development (CPD) points, supporting their ongoing professional training and education.

The inaugural event, which takes place on Tuesday, November 25, at Conway Hall, has received CPD accreditation in principle from the CPD Certification Service. This recognition confirms that the symposium meets rigorous standards for educational quality, structure, and relevance, ensuring attendees benefit from a credible, evidence-based learning experience.

Professional development for clinicians in medical cannabis

The symposium is designed to offer UK healthcare professionals clinically grounded and expert-led education on cannabis-based products for medicinal use (CBPMs).

It will feature presentations, case studies, and workshops focused on enhancing clinical understanding and improving patient care.

CPD, which refers to the ongoing education of healthcare practitioners after formal qualification, is essential to ensure clinicians maintain up-to-date knowledge and safe practice.

In emerging fields such as medical cannabis, accredited learning opportunities also help build confidence and expertise among prescribers.

Currently, only around 180 doctors on the GMC Specialist Register are actively prescribing medical cannabis, representing less than 1% of those authorised to do so.

With around 80,000 patients expected to receive CBPM treatment in the UK by 2025, there is a pressing need for more trained prescribers to meet patient demand and uphold care standards.

What to expect from the event

The symposium will explore topics such as clinical governance, NHS integration, product consistency and safety, and the science of the endocannabinoid system. Expert speakers will present the latest evidence on the use of cannabis-based medicines in women’s health, psychiatry, neurodivergence, and neurodegenerative conditions.

Alongside the main programme, a workshop series led by the Medical Cannabis Clinicians Society (MCCS) will provide hands-on, skills-based training. These sessions will introduce the fundamentals of medical cannabis prescribing, including formulations, clinical indications, safety considerations, and professional responsibilities. Participants will have opportunities to engage directly with experienced prescribers through Q&A sessions and interactive learning.

Professor Mike Barnes, Chair of the MCCS, said the symposium would represent a ‘significant step forward for clinicians’, with the potential to benefit ‘many thousands of patients’ across the UK.

Accredited training and certification

Organised in partnership with Curaleaf Laboratories and the Medical Cannabis Clinicians Society, the symposium aims to empower healthcare professionals to integrate cannabis-based treatments into their clinical practice confidently.

Clinicians will receive CPD points for each session attended, with formal certification provided after the event.

View the full agenda here

TopicsCannabis Based Medicinal Productscannabis in healthcareCannabis researchcannabis symposiumCBPMsclinical governanceclinician trainingContinuing Professional Development

Ben Stevens

Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.

More from Ben

Spotted an error, or have a tip? Contact the newsroom.

Up next · Clinical Research

Helius Therapeutics to Supply New Phase 2 Cannabis Sleep Trial

Ben Stevens · 20 October 2026

More